Enanta Pharmaceuticals Inc (NASDAQ:ENTA) — Market Cap & Net Worth
Market Cap & Net Worth: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has a market capitalization of $364.65 Million ($364.65 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13981 globally and #3349 in its home market, demonstrating a -5.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enanta Pharmaceuticals Inc's stock price $12.52 by its total outstanding shares 29125402 (29.13 Million). Also see how large is Enanta Pharmaceuticals Inc's balance sheet for a full breakdown of the balance sheet.
Enanta Pharmaceuticals Inc Market Cap History: 2015 to 2026
Enanta Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $961.72 Million to $364.65 Million (-10.17% CAGR). Also see Enanta Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Enanta Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #381 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1362 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #205 of 263 |
Weight: Enanta Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enanta Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enanta Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Enanta Pharmaceuticals Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.03x
Enanta Pharmaceuticals Inc's market cap is 7.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $975.70 Million | $88.27 Million | $21.67 Million | 11.05x | 45.03x |
| 2017 | $1.71 Billion | $102.81 Million | $17.71 Million | 16.62x | 96.50x |
| 2018 | $2.06 Billion | $206.62 Million | $71.96 Million | 9.98x | 28.67x |
| 2019 | $1.80 Billion | $205.20 Million | $46.38 Million | 8.77x | 38.79x |
| 2020 | $1.23 Billion | $122.47 Million | -$36.17 Million | 10.01x | N/A |
| 2021 | $2.18 Billion | $97.07 Million | -$79.00 Million | 22.44x | N/A |
| 2022 | $1.35 Billion | $86.16 Million | -$121.75 Million | 15.73x | N/A |
| 2023 | $274.07 Million | $79.20 Million | -$133.82 Million | 3.46x | N/A |
| 2024 | $167.47 Million | $67.64 Million | -$116.05 Million | 2.48x | N/A |
| 2025 | $459.31 Million | $65.32 Million | -$81.89 Million | 7.03x | N/A |
Competitor Companies of ENTA by Market Capitalization
Companies near Enanta Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Enanta Pharmaceuticals Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Enanta Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Enanta Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Enanta Pharmaceuticals Inc's market cap moved from $961.72 Million to $ 364.65 Million, with a yearly change of -10.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $364.65 Million | -20.61% |
| 2025 | $459.31 Million | +174.26% |
| 2024 | $167.47 Million | -38.89% |
| 2023 | $274.07 Million | -79.77% |
| 2022 | $1.35 Billion | -37.79% |
| 2021 | $2.18 Billion | +77.62% |
| 2020 | $1.23 Billion | -31.85% |
| 2019 | $1.80 Billion | -12.78% |
| 2018 | $2.06 Billion | +20.71% |
| 2017 | $1.71 Billion | +75.16% |
| 2016 | $975.70 Million | +1.45% |
| 2015 | $961.72 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Enanta Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $364.65 Million USD |
| MoneyControl | $364.65 Million USD |
| MarketWatch | $364.65 Million USD |
| marketcap.company | $364.65 Million USD |
| Reuters | $364.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more